-
www.talkingquality.ahrq.gov/data/visualizations/ed-visit-suicidal-ideation.html
February 01, 2021 - presents statistics on ED visits related to suicidal ideation or suicide attempt among individuals age 5 years … visits per 100,000 population related to suicidal ideation or suicide attempt for individuals ages 5-24 years … , 25-64 years, and 65+ years.
-
www.talkingquality.ahrq.gov/cahps/about-cahps/25timeline.html
April 01, 2024 - Assessment of Healthcare Providers and Systems (CAHPS®)
About CAHPS
Celebrating 25 Years … Patient Experience
CAHPS Announcements
Contact CAHPS
Celebrating 25 Years … of the CAHPS Program
For 25 years, AHRQ has developed evidence-based surveys to support healthcare … homes
Care for specific health conditions
Health plans and related programs
Access CAHPS ® : 25 Years … reviewed April 2024
Page originally created October 2020
Internet Citation: Celebrating 25 Years
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/preventive/chipra-202-tech-specs.pdf
October 11, 2018 - Parents' Evaluation of Developmental Status (PEDS), birth - 8 years
Non-recommended tools are those … " using "Ages and
Stages Questionnaire (ASQ), 2 months - 5 years User Defined QDM Value Set (1.1.1.1) … "
using "Bayley Infant Neuro-developmental Screen (BINS), 3 months - 2 years User Defined QDM Value Set … " using "Child
Development Inventory (CDI), 18 months - 6 years User Defined QDM Value Set (1.1.1.1)" … " using "Child Development Review-Parent Questionnaire (CDR-PQ), 18 months - 5 years User
Defined QDM
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-212-appendix-2.pdf
January 17, 2024 - CORTICOSTEROIDS (ICS)
ICS NDC Code Brand Name Generic Product Name Route Drug ID Device
FDA-Age
(Years … and
older N N N Y
ICS NDC Code Brand Name Generic Product Name Route Drug ID Device
FDA-Age
(Years … Budesonide
budesonide 0.5 mg/2 mL
inhalation suspension inhalation d04276 Nebulizer
12 mon –
8 years … Budesonide
budesonide 0.5 mg/2 mL
inhalation suspension inhalation d04276 Nebulizer
12 mon –
8 years … and
older N N N Y
ICS NDC Code Brand Name Generic Product Name Route Drug ID Device
FDA-Age
(Years
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/measure_retirement/supplemental-materials/supplementaldoc2.pdf
September 01, 2014 - 3 years:
28% (5)
Enrollees age
1 year:
19, 61
Age 2 years:
23, 50
Age 3 years:
18, 35 … Chlamydia
Screening
(females ages 16–
20 years)
Sexually
active females
ages 16–20
years (MAX … Adolescent
Well-Care Visits:
Persons Ages 12–
21 Years
Enrollees
ages 12–17
years (MAX
b
): … –6
years: 86, 92
Ages 7–11
years: 86, 93
Ages 12–19
years: 86, 92
Enrollees
ages 12–24 … months:
Mixed
Ages 25
months–6
years:
Downward
Ages 7–11
years: Mixed
Ages 12–19
years
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-230-tech-specs.pdf
July 12, 2019 - CHIPRA 230: Technical Specifications
1
The percentage of children, ages 2 through 17 years … For children
≥16 years of age, BMI score is sufficient. … Weight Classification Using BMI percentile, children 2 through 17 years of age can be classified
into … Ages 2 through 17 years of age. … BMI score qualifies if child is 16 or 17 years of age.
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-201-asthma-section-2-tech-specs.pdf
March 12, 2019 - Technical Specifications
This measure assesses the percentage of children, ages 1 through 17 years … record data and is calculated as a
percentage as follows:
Percentage of children ages 1 through 17 years … Ages Children no younger than 1 year on January 1 of the measurement year
but younger than 18 years … with (acute) exacerbation 493.92
Denominator The number of children ages 1 through 17 years … indicating cystic fibrosis or bronchiectasis (Table 2)
Specification
• Children younger than 6 years
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-157-section-6b.pdf
August 10, 2018 - Ref.
6-12 years old / 0.324d 0.322d 0.325d 0.310d 0.310d 0.309d
1-5 years old / 0.728 0.726 0.735 … Ref.
6-12 years old / 0.324d 0.322d 0.325d 0.310d 0.310d 0.309d
1-5 years old / 0.728 0.726 0.735 … Ref.
6-12 years old / 0.329d 0.327d 0.327d 0.310d 0.310d 0.309d
1-5 years old / 0.738 0.735 0.739 … Ref.
6-12 years old / 0.411d 0.411d 0.413d 0.357d 0.359d 0.359d
1-5 years old / 0.893 0.892 0.904 … Ref.
6-12 years old / 0.411d 0.411d 0.413d 0.357d 0.358d 0.359d
1-5 years old / 0.894 0.893 0.905
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/sops/surveys/hospital/facilscanform.pdf
November 18, 2019 - Less than 1 year d. 11 to 15 years
b. 1 to 5 years e. 16 to 20 years
c. 6 to 10 years f. … 21 years or more
2. … Less than 1 year d. 11 to 15 years
b. 1 to 5 years e. 16 to 20 years
c. 6 to 10 years f. 21 … years or more
3. … Less than 1 year d. 11 to 15 years
b. 1 to 5 years e. 16 to 20 years
c. 6 to 10 years f.
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/sops/surveys/hospital/facilscanform.doc
November 15, 2019 - Less than 1 year
(
d.
11 to 15 years
(
b.
1 to 5 years
(
e.
16 to 20 years
(
c.
6 to 10 years … (
f.
21 years or more
2. … Less than 1 year
(
d.
11 to 15 years
(b.
1 to 5 years
(
e.
16 to 20 years
(
c.
6 to 10 years
( … f.
21 years or more
3. … Less than 1 year
(
d.
11 to 15 years
(
b.
1 to 5 years
(
e.
16 to 20 years
(
c.
6 to 10 years
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/overview/background/measures-AS-1.pdf
December 16, 2010 - Numerator: For 12-24 months, 25 months-6 years: One or more visits with a primary
care physician during … For 7-11 years, 12-19 years:
One or more visits with a primary care physician during the measurement … Denominator: Members who are 12 months through 24 months, 25 months through 6
years, 7 years through … 11 years, and 12 years through 19 years of age as of
December 31 of the measurement year.
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-section-2-tech-specs.pdf
November 01, 2014 - Specification – State Level
Measure Description
The percentage of children and adolescents 1 to 20 years … Eligible Population
Ages 1 to 20 years by December 31 of the measurement year. … 1-5 years
6-11 years
12-17 years
18-20 years
Total. … Ages 1 year of age to 17 years as of December 31 of the measurement year. … Report three
age stratifications and a total rate:
1–5 years.
6–11 years.
12–17 years.
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-156-section-6b.pdf
January 01, 2013 - Ref.
6-12 Years Old / 0.908 0.929 0.946 0.946 0.948 0.947
1-5 Years Old / 0.795 0.809 0.775 0.774 … Ref.
6-12 Years Old / 0.906 0.928 0.944 0.944 0.947 0.947
1-5 Years Old / 0.795 0.808 0.775 0.774 … Ref.
6-12 Years Old / 0.895 0.916 0.936 0.936 0.940 0.941
1-5 Years Old / 0.788 0.800 0.772 0.771 … Ref.
6-12 years old / 0.324d 0.322d 0.325d 0.310d 0.310d 0.309d
1-5 years old / 0.729 0.727 0.735 … Ref.
6-12 years old / 0.325d 0.323d 0.325d 0.311d 0.311d 0.310d
1-5 years old / 0.731 0.729 0.737
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/toolkits/input-file-specifications.xlsx
January 01, 2014 - medical claims source table
Blank Blank Blank Note: Data for comorbidity claims cover a total of two years … had any comorbidities that involved the dermatological body system numeric (1/0) Calculated using 2 years … had any comorbidities that involved the genitourinary body system numeric (1/0) Calculated using 2 years … had any comorbidities that involved the hematological body system numeric (1/0) Calculated using 2 years … had any comorbidities that involved the immunological body system numeric (1/0) Calculated using 2 years
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/sops/surveys/2019-pharmacy-sops-database-report-appendix.pdf
January 01, 2019 - 3 Years to <6
Years
6 Years to <12
Years
12 Years or
More
# Community Pharmacies 88 87 179 … 3 Years to <6
Years
6 Years to <12
Years
12 Years or
More
# Community Pharmacies 88 87 179 … <6 Months
6 Months to <1
Year
1 Year to <3
Years
3 Years to <6
Years
6 Years to <12
Years … <6 Months
6 Months to <1
Year
1 Year to <3
Years
3 Years to <6
Years
6 Years to <12
Years … <6 Months
6 Months to <1
Year
1 Year to <3
Years
3 Years to <6
Years
6 Years to <12
Years
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-145-materials-vii-a.pdf
January 01, 2010 - code in the
measurement
year (2011)
Follow-
% of
Denominator
up Visit
2010-2011
4-5 years … 245,024 126,173 51% 10,620 8% 2,489 23.43% 1,780 16.76% 5,703 53.70% 7,249 68.25%
6-12 years 713,045 … 377,224 53% 66,825 18% 14,798 22.14% 8,776 13.13% 34,675 51.88% 44,888 67.16%
13-18 years 490,828 … 10,055 7% 2,306 22.93% 1,331 13.24% 3,159 31.41% 5,131 51.03%
4-18 years 902,756 498,472 55% 45,574 … 5% 664 16.96% 411 10.50% 1,707 43.61% 2,204 56.30%
13-18 years 93,703 32,379 35% 950 3% 147 15.47%
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-126-section-2-technical-specs.pdf
April 30, 2018 - Children
Administrative Specification
Measure Description
The percentage of children 0 to 20 years … Eligible Population
Product Line Medicaid
Ages 0 to 20 years by December 31 of the measurement year … 0-5 years
6-11 years
12-17 years
18-20 years
Total
The total is the sum of the
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/evidencenow/heart-health/strategies-to-better-manage-lipids.pptx
November 01, 2016 - Population Recommendation Grade
Adults ages 40-75 years with no symptoms or history of CVD and a calculated … for the prevention of CVD events when all of the following criteria are met:
They are ages 40 to 75 years … and calculation of 10-year CVD event risk requires
universal lipid screening in adults ages 40 to 75 years … #›
4
USPSTF Recommendation November 2016 (2)
Population Recommendation Grade
Adults ages 40-75 years … I
Children and adolescents
younger than age 20 years The USPSTF concludes that the current evidence
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/evidencenow/heart-health/aspirin-asa-measure.pptx
April 01, 2016 - some stroke)
Cardiovascular Disease (2)
Leading killer
Huge declines in CVD death in the past 20 years … , and are willing to take low-dose aspirin daily for at least 10 years. … Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and … ar1e willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. … and harms of aspirin use to prevent CVD and colorectal cancer in adults younger than age 50 years.
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-155-section-6-b-measure.pdf
January 01, 2013 - Ref.
6-12 years old / 0.779d 0.783d 0.729d 0.765d 0.765d 0.764d
1-5 years old / 0.639d 0.643d 0.561d … Ref.
6-12 years old / 0.502d 0.502d 0.513d 0.485d 0.485d 0.486d
1-5 years old / 0.969 0.968 1.008 … Ref.
6-12 years old / 0.457d 0.457d 0.459d 0.423d 0.424d 0.425d
1-5 years old / 0.976 0.976 0.973 … Ref.
6-12 years old / 0.461d 0.461d 0.462d 0.389d 0.390d 0.390d
1-5 years old / 0.970 0.970 0.976 … Ref.
6-12 years old / 0.432d 0.432d 0.429d 0.452a 0.452d 0.459d
1-5 years old / 1.037 1.037 1.023